Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President, Representative Director, Gyo Sagara; "ONO") today announced that ONO received a manufacturing and marketing approval in ® Japan for Parsabiv (generic name: etelcalcetide hydrochloride) Intravenous Injection Syringe for Dialysis 2.5 mg, 5 mg and 10 mg ("Parsabiv Syringe"), a calcimimetic agent.
With this approval, Parsabiv is available as a new intravenous injection syringe for dialysis, in addition to the intravenous injection for dialysis already approved for the treatment of secondary hyperparathyroidism in patients on hemodialysis.
Parsabiv Syringe, which is pre-filled with the drug in its syringe, can allow the drug to be administered smoothly. We believe, therefore, that it serves not only to reduce the burden of health professionals involved in the treatment of secondary hyperparathyroidism under hemodialysis, but also to reduce the infection risks. Since the product name of Parsabiv is put on the syringe, it is also served to prevent product mix-up.
About secondary hyperparathyroidism
Secondary hyperparathyroidism, one of complications of chronic renal failure, is a pathological condition where excessive parathyroid hormone (PTH) is secreted by the parathyroid gland. Excessive PTH secretion promotes phosphorus and calcium efflux from bone which may cause symptoms including bone and joint pain. Further, it is reported that vascular calcification due to accumulation of phosphorus and calcium from bone in vessels aggravates risk of cardiovascular events which adversely affects life prognosis . *
＊Japanese Clinical Practice Guideline for the management of chronic kidney disease-mineral and bone disorders (CKD-MBD) issued by the Japanese Society for Dialysis Therapy in 2012.
Parsabiv activates the calcium sensing receptor in the parathyroid and suppresses excessive PTH secretion, and also lowers phosphorus and serum calcium level.
Parsabiv is the first intravenous calcium receptor agonist in the world which ONO in-licensed from the former U.S company, KAI Pharmaceuticals, Inc. (later acquired by Amgen) in September 2011. In Japan, ONO received a manufacturing and marketing approval for Parsabiv in December 2016, ® and launched it under the product name of "Parsabiv Intravenous Injection for Dialysis 2.5 mg, 5 mg and 10 mg" in February 2017.
Abroad, Parsabiv was approved in Europe in November 2016 and in the U.S in February 2017 for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.
® Overview of Parsabiv Intravenous Injection Syringe for Dialysis 2.5 mg, 5 mg and 10 mg ®
Parsabiv ®Intravenous Injection Syringe for Dialysis 2.5mg
Parsabiv® Intravenous Injection Syringe for Dialysis 5mg
Parsabiv ®Intravenous Injection Syringe for Dialysis 10mg
Secondary hyperparathyroidism in patients on hemodialysis
In adults, Parsabiv is usually administered into venous line of the dialysis circuit at the end of dialysis session during rinse back at a dose of 5 mg as etelcalcetide 3 times a week as a starting dose. Dosage and Thereafter, the dose may be adjusted in a range from 2.5 mg to 15 mg as Administration necessary and administered 3 times a week at the end of dialysis session during rinse back while parathyroid hormone (PTH) and serum calcium level should be carefully monitored in patients.
June 29, 2020
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
To read more Press Release articles, click here.